Ideas

Mesenchymal stem cell therapy for cardiac diseases: Mesenchymal stem cell therapy inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 22/December/2018, 9.38 pm
Mesenchymal stem cell therapy for cardiac diseases: Mesenchymal stem cell therapy inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 22/December/2018, 9.38 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the journal Nature,  by Prof Dimmler,…

read more

Molecular therapy for TIIDM and Metabolic defects:Mesencephalic astrocyte-derived neurotrophic factor (MANF)  increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 21/December/2018, 10.43 pm
Molecular therapy for TIIDM and Metabolic defects:Mesencephalic astrocyte-derived neurotrophic factor (MANF)  increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 21/December/2018, 10.43 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the “Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27701, USA; Department of…

read more

Activator protein(AP-1)-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  a chemical compound that induces  AP-1 activity, Epicatechin and Matrine (VAEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/December/2018, 10.32 pm
Activator protein(AP-1)-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  a chemical compound that induces  AP-1 activity, Epicatechin and Matrine (VAEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/December/2018, 10.32 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more

Valproic acid-based therapy for TIIDM and Metabolic defects: Valproic acid (brand names: Convulex, Depakote, epilim, stavzor and others), a drug used to treat seizures/epilepsy, increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 20/December/2018, 11.23 pm
Valproic acid-based therapy for TIIDM and Metabolic defects: Valproic acid (brand names: Convulex, Depakote, epilim, stavzor and others), a drug used to treat seizures/epilepsy, increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 20/December/2018, 11.23 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the “Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27701, USA; Department of…

read more

Valproic acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  Valproic acid, Epicatechin and Matrine (VAEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 20/December/2018, 11.08 pm
Valproic acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  Valproic acid, Epicatechin and Matrine (VAEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 20/December/2018, 11.08 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: AP-1 (Activator protein-1) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 20/December/2018, 10.59pm
Molecular therapy for body weight control, energy homeostasis and TIIDM: AP-1 (Activator protein-1) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 20/December/2018, 10.59pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more
Start Typing